Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy
Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy for Screening of Barrett's Esophagus: A Prospective Tandem Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a pilot, single center, prospective, tandem study. All veteran patients with Barrett's esophagus scheduled for an upper EGD at Veterans Affairs Medical Center (Kansas City, MO, USA) for check-up of BE will be asked to swallow the pillcam prior to an EGD. A member of the research team will approach a potential subject to discuss participation in the study, including background of the proposed study, inclusion and exclusion criteria, benefits and risks of the procedures and follow-up. If this is of interest to the subject, the informed consent form is discussed and presented. The subject must sign the consent form prior to enrollment. This form will have prior approval of the study site's Institutional Review Board (IRB). Failure to obtain informed consent renders the subject ineligible for the study
Eligible subjects at the participating institution who meet the inclusion criteria for this study will be offered the opportunity to participate in this clinical trial. To ensure that subjects are approached for potential study participation without bias, a Subject Screening Log will be maintained. This Log will track the basic demographic information of each subject approached for clinical trial inclusion and the resulting reason for exclusion from the clinical study if applicable.
The duration of the study is expected to be approximately 12 months. Enrollment of Study patients will cease when approximately 20 patients have been enrolled.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- Kansas City VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients age: ≥ 18 years
- Patients with BE length ≥ 1cm undergoing upper endoscopy
- Willingness to undergo both unsedated, capsule endoscopy and conventional EGD
- Ability to provide written, informed consent and understand the responsibilities of trial participation
Exclusion Criteria:
- Coagulopathy with INR > 1.5, thrombocytopenia with platelet counts < 50,000
- Pregnant or planning a pregnancy during the study period
- Dysphagia
- Known esophageal diverticulum or stricture
- Swallowing disorder
- Known luminal, gastrointestinal stricture
- History of esophageal, gastric surgery
- Esophageal or GI motility disorder
- Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines
- Known or suspected gastrointestinal obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and profile.
- Subjects with cardiac pacemakers or other implanted electromedical devices.
- Anticipated magnetic resonance imaging within 1 week of capsule ingestion
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pill cam and EGD
Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
|
Patient is asked to swallow the esophageal capsule.
Patient will undergo standard EGD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The overall diagnostic accuracy of capsule endoscopy in predicting the presence and extent of Barrett's esophagus in comparison to standard esophagogastroduodenoscopy
Time Frame: 1 year
|
The ability to accurately predict the presence of Barrett's esophagus by capsule endoscopy and standard EGD will be measured.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment related adverse events of capsule endoscopy in comparison to standard esophagogastroduodenoscopy
Time Frame: 1 year
|
Wireless capsule endoscopy is generally considered safe.
Potential risks resulting from capsule endoscopy are reported low and may include discomfort while swallowing, accidental aspiration and capsule retention leading to small bowel obstruction and perforation.
the investigator will measure tolerability of capsule endoscopy as well as standard endoscopy using visual analogue scale.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009 Dec 24;361(26):2548-56. doi: 10.1056/NEJMcp0902173. No abstract available. Erratum In: N Engl J Med. 2010 Apr 15;362(15):1450.
- Eliakim R, Sharma VK, Yassin K, Adler SN, Jacob H, Cave DR, Sachdev R, Mitty RD, Hartmann D, Schilling D, Riemann JF, Bar-Meir S, Bardan E, Fennerty B, Eisen G, Faigel D, Lewis BS, Fleischer DE. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005 Aug;39(7):572-8. doi: 10.1097/01.mcg.0000170764.29202.24.
- Chang JY, Talley NJ, Locke GR 3rd, Katzka DA, Schleck CD, Zinsmeister AR, Dunagan KT, Wu TT, Wang KK, Prasad GA. Population screening for barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc. 2011 Dec;86(12):1174-80. doi: 10.4065/mcp.2011.0396.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PS0084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett Esophagus
-
NCT03621319TerminatedBarrett's Esophagus | High-grade Dysplasia in Barrett Esophagus | Low Grade Dysplasia in Barrett Esophagus
-
NCT05628441CompletedBarrett Esophagus | Barrett Adenocarcinoma
-
NCT03205501CompletedEsophageal Cancer | Barrett Esophagus | Dysplasia in Barrett Esophagus
-
NCT01618643CompletedBarrett Esophagus | Barrett Adenocarcinoma | Barrett Metaplasia | Barrett Oesophagitis With Dysplasia
-
NCT03240679TerminatedBarretts Esophagus With High Grade Dysplasia | Barrett Adenocarcinoma
-
NCT05276791Not yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
NCT05745857RecruitingEsophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barrett Oesophagitis With Dysplasia
-
NCT02200250WithdrawnBarretts Esophagus
-
NCT06381583CompletedEsophageal Cancer | Esophageal Neoplasms | Gastroesophageal Reflux | Barrett Esophagus | Esophageal Adenocarcinoma | Reflux Disease | Barretts Esophagus With High Grade Dysplasia | Barrett Adenocarcinoma | Esophagus Cancer | Barrett's Esophagus Without Dysplasia
Clinical Trials on Pill cam
-
NCT00663637UnknownPneumonia | Mechanical Ventilation
-
NCT07411612RecruitingInflammation | Postoperative Complications | Blood Brain Barrier Defect | Delirium - Postoperative | Neuronal Damage
-
NCT07329244Not yet recruitingTooth Demineralization | Tooth Sensitivity | Tooth Eruption Disorder | Tooth Sensitivity After Composite Restorations | Enamel Mineralization Disorders | Indirect Restoration
-
NCT04222166CompletedOrthopedic Disorder | Wound
-
NCT06779669Active, not recruiting
-
NCT04467515TerminatedAdvanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
-
NCT03732443WithdrawnDelirium | Critical Illness | Family Members
-
NCT02760446CompletedPatients With Mental Confusion
-
NCT02779244Completed